These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 15275718

  • 1. Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.
    Buchholz TA, Huang EH, Berry D, Pusztai L, Strom EA, McNeese MD, Perkins GH, Schechter NR, Kuerer HM, Buzdar AU, Valero V, Hunt KK, Hortobagyi GN, Sahin AA.
    Int J Radiat Oncol Biol Phys; 2004 Aug 01; 59(5):1337-42. PubMed ID: 15275718
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
    Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Hortobagyi GN, Buchholz TA.
    J Clin Oncol; 2004 Dec 01; 22(23):4691-9. PubMed ID: 15570071
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Locoregional failure 15 years after mastectomy in women with one to three positive axillary nodes with or without irradiation the significance of tumor size.
    Fodor J, Polgár C, Major T, Németh G.
    Strahlenther Onkol; 2003 Mar 01; 179(3):197-202. PubMed ID: 12627264
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
    Truong PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E.
    Int J Radiat Oncol Biol Phys; 2005 Apr 01; 61(5):1337-47. PubMed ID: 15817335
    [Abstract] [Full Text] [Related]

  • 9. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG, Berry DA, Broadwater G, Cowan D, Cox K, Griffin S, Miller A, Tse J, Novotny D, Persons DL, Barcos M, Henderson IC, Liu ET, Thor A, Budman D, Muss H, Norton L, Hayes DF.
    J Clin Oncol; 2005 Jul 01; 23(19):4287-97. PubMed ID: 15994142
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer.
    Moon YW, Jeung HC, Rha SY, Choi YH, Yang WI, Chung HC.
    Breast Cancer Res Treat; 2007 Jul 01; 104(1):31-7. PubMed ID: 17587181
    [Abstract] [Full Text] [Related]

  • 13. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
    Orlando L, Del Curto B, Gandini S, Ghisini R, Pietri E, Torrisi R, Balduzzi A, Cardillo A, Dellapasqua S, Veronesi P, Viale G, Goldhirsch A, Colleoni M.
    Breast; 2008 Oct 01; 17(5):506-11. PubMed ID: 18456496
    [Abstract] [Full Text] [Related]

  • 14. Impact of postmastectomy radiation on locoregional recurrence in breast cancer patients with 1-3 positive lymph nodes treated with modern systemic therapy.
    Tendulkar RD, Rehman S, Shukla ME, Reddy CA, Moore H, Budd GT, Dietz J, Crowe JP, Macklis R.
    Int J Radiat Oncol Biol Phys; 2012 Aug 01; 83(5):e577-81. PubMed ID: 22560546
    [Abstract] [Full Text] [Related]

  • 15. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with node-negative patients after breast-conserving surgery and whole-breast radiotherapy.
    Truong PT, Jones SO, Kader HA, Wai ES, Speers CH, Alexander AS, Olivotto IA.
    Int J Radiat Oncol Biol Phys; 2009 Feb 01; 73(2):357-64. PubMed ID: 18676091
    [Abstract] [Full Text] [Related]

  • 16. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
    Arsenault D, Hurley J, Takita C, Reis IM, Zhao W, Rodgers S, Wright JL.
    Am J Clin Oncol; 2015 Aug 01; 38(4):348-52. PubMed ID: 23799288
    [Abstract] [Full Text] [Related]

  • 17. The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: an analysis of prospective data from British Columbia and the M. D. Anderson Cancer Center.
    Truong PT, Woodward WA, Thames HD, Ragaz J, Olivotto IA, Buchholz TA.
    Int J Radiat Oncol Biol Phys; 2007 May 01; 68(1):59-65. PubMed ID: 17321065
    [Abstract] [Full Text] [Related]

  • 18. Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.
    D'Alessandro C, Dellapasqua S, Orlando L, Santoro L, Maisonneuve P, Torrisi R, Balduzzi A, Scarano E, Ghisini R, Peruzzotti G, Goldhirsch A, Colleoni M.
    Breast J; 2008 May 01; 14(5):435-41. PubMed ID: 18821931
    [Abstract] [Full Text] [Related]

  • 19. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy.
    Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martinec J.
    Clin Cancer Res; 1996 Sep 01; 2(9):1509-13. PubMed ID: 9816327
    [Abstract] [Full Text] [Related]

  • 20. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.
    Anticancer Res; 2004 Sep 01; 24(3b):2061-8. PubMed ID: 15274401
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.